<DOC>
	<DOC>NCT01970059</DOC>
	<brief_summary>The aim of present study is to evaluate the efficacy and safety of Extended-Release Carvedilol Sulfate versus in Patients With Mild or Moderate Primary Hypertension</brief_summary>
	<brief_title>A Phase Ⅲ Study of Extended-Release Carvedilol Sulfate for the Treatment of Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Carvedilol</mesh_term>
	<mesh_term>Metoprolol</mesh_term>
	<criteria>Males or Females Aged from 18 to 70 years Had a history of essential hypertension Average sitting diastolic blood pressure≧90mmHg，but≦109mmHg Malignant hypertension Average sitting systolic blood pressure≧180mmHg Type 2 diabetes with hemoglobin A1c≥9% Type 1 diabetes New York Heart Association class ⅡⅣ congestive heartfailure Unstable angina Second or third degree heart block or history of sick sinus syndrome unless a pacemaker was in place Atrial fibrillation Bradycardia (&lt;60 bpm, seated) Asthma or other obstructive pulmonary disease History of myocardial infarction Stroke in the 6 months before screening Known contraindications to βadrenergic blocker therapy Glutamicoxaloacetic transaminase and/or glutamicpyruvic transaminase＞3 times upper limit of normal Crea＞2 times upper limit of normal Pregnancy or lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Hypertension</keyword>
</DOC>